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A comparison of New York’s traditional communicable
disease surveillance system for diarrhea-associated
hemolytic uremic syndrome with hospital discharge data
showed a sensitivity of 65%. Escherichia coli O157:H7 was
found in 63% of samples cultured from hemolytic uremic
syndrome patients, and samples were more likely to be
positive when collected early in illness.
D
iarrhea-associated hemolytic uremic syndrome (HUS)
is a major cause of acute renal failure in children (1).
Various studies have demonstrated that Shiga toxin–pro-
ducing Escherichia coli are the etiologic agents in most
cases of diarrhea-associated HUS (2,3). In the United
States,  E. coli O157:H7 is the most common Shiga
toxin–producing  E. coli, causing an estimated 73,480
infections (4); HUS develops in 3%–15% of patients soon
after the onset of diarrhea (5,6). 
The risk factors associated with the progression of E.
coli O157 to HUS include very young or old age, elevated
leukocyte count, and use of antimicrobial treatment or
antimotility agents (7–11). Little is known about the clini-
cal features that could identify patients at high risk for
HUS. In New York, both E. coli O157 infection and diar-
rhea-associated HUS became reportable in July 1994.
Since then, the annual incidence rate for E. coli O157 per
100,000 population has ranged from 1.6 in 1995 to 8.5 in
1999; the annual incidence rate for diarrhea-associated
HUS per 100,000 population has ranged from 0.1 in 1995
to 0.2 in 1999. 
HUS is a severe disease that results in hospitalization.
Our surveillance and hospital discharge data were used to
evaluate the HUS surveillance system, estimate the num-
ber of diarrhea-associated HUS cases, and study the epi-
demiologic and clinical features of HUS in New York. 
The Study
A confirmed case of HUS was defined as the acute
onset of anemia with microangiopathic changes (i.e.,
schistocytes, burr cells, or helmet cells) on peripheral
blood smear, acute renal injury (i.e., hematuria, protein-
uria, or elevated creatinine level), and a low platelet count
(platelets <150,000/mL) within 3 weeks of an acute diar-
rheal illness. A probable case of HUS was defined as the
acute onset of anemia with microangiopathic changes,
acute renal injury, and a low platelet count without a histo-
ry of diarrhea in the preceding 3 weeks; or hemolytic ane-
mia without confirmed microangiopathic changes, acute
renal injury, and a low platelet count within 3 weeks of an
acute diarrheal illness (12). 
Hospital admission notes, laboratory reports, and dis-
charge summaries were requested for patients who had
HUS (International Classification of Diseases, 9th
Revision, Clinical Modification [ICD-9-CM] code 283.11)
listed as their primary or any secondary diagnosis for 1998
and 1999. All medical charts were reviewed, and patients
were classified as having a confirmed, probable, or unde-
termined HUS case. Persons with multiple hospitalizations
were counted only once. The records from case reports and
medical charts were matched by last name, first name, and
date of birth. The capture-recapture method was used to
evaluate the completeness of HUS reporting and to esti-
mate the “true” number of HUS cases and the 95% confi-
dence interval (13). 
Data from medical charts regarding demographic char-
acteristics (age, sex, race, month of admission, hospital
length of stay), clinical features at admission (vomiting,
fever, bloody stool), and antimicrobial therapy were
extracted for all confirmed or probable case-patients.
Laboratory variables were obtained for patients within 7
days before and 3 days after the HUS diagnosis and includ-
ed the lowest hematocrit, lowest platelet count, highest
blood urea nitrogen (BUN), and highest creatinine concen-
trations. The Fisher exact test was used to determine the
proportion of demographic and clinical characteristics
among HUS patients with or without stool isolates for E.
coli O157:H7, and the two-tailed Student t test was used to
determine the significance of differences between their
mean laboratory variables. 
Forty-five HUS case-patients reported to the New York
communicable disease surveillance system for 1998
through 1999 were listed as being hospitalized; the med-
ical charts of 44 of these patients were available for review.
We requested 542 medical records that had a primary or
secondary discharge diagnosis listed as HUS during the
same period; 421 (78%) charts were received. After chart
review, 234 records were from New York State residents,
excluding New York City, and 201 patients remained for
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patients had confirmed HUS, 10 patients had probable
HUS, and 142 patients either had incomplete information
to determine HUS status or did not have HUS. Among
these 142 patients, 9 patients had no laboratory reports, 23
patients had renal failure and anemia with microangiopath-
ic changes but no diarrhea; and 110 patients had no renal
failure or no microangiopathic changes. Stool samples
from 12 of these 142 patients were cultured for E. coli;
none was positive.
HUS surveillance data were matched against hospital
discharge data by last name, first name, and date of birth.
Thirty-three confirmed and 5 probable cases were in both
systems, 4 confirmed and 3 probable cases were only in
the surveillance system, and 16 confirmed and 5 probable
cases were only in the hospital system. The “true” total
number of confirmed or probable HUS cases in New York
was estimated to be 70 (95% confidence interval [CI] = 63
to 75), and the sensitivity of our surveillance system for
reporting HUS was 65%. 
The demographic, clinical features, and laboratory
results of 53 confirmed and 12 probable diarrhea-associat-
ed HUS cases from either data system were studied. The
average annual incidence was significantly greater among
children <5 years of age (relative risk [RR] 17, 95% confi-
dence interval [CI] 8.9 to 32) than among patients 15–64
years of age and was greater among female than male
patients (RR 2.1, 95% CI 1.2 to 3.8) (Table 1). The medi-
an length of hospital stay was 11 days. Review of clinical
features indicated that 62 (95%) had diarrhea; 46 (71%)
had bloody stools. While hospitalized, 20 (31%) patients
received antimicrobial agents and 19 were treated before
HUS developed. Thrombocytopenia (platelets
<150,000/mL) was present in 90% of the patients, and
85% had hemolytic anemia with microangiopathic
changes on peripheral blood smear. HUS patients <15
years of age were more likely to have fever (64%) and
bloody stools (82%) than those >15 years of age (19% and
54%, respectively).
Six patients (9%), ages 3 to 89 years, died while hospi-
talized; two of these deaths were outbreak related. All six
patients had bloody diarrhea and blood transfusions,
leukocyte counts >18,000, BUN levels >63, and serum
creatinine levels >2.3. Samples from five of six were cul-
ture positive for E. coli O157:H7.
Of the 65 confirmed or probable HUS patients, 54
(83%) had their stool or urine tested for E. coli O157:H7;
34 (63%) of these patients had positive results (33 stools
and 1 urine). Of the 34 culture-confirmed patients, 30 were
reported to the surveillance system, and 4 patients received
a diagnosis only in the hospital system. A significantly
higher proportion of patients with samples culture-positive
for E. coli O157 patients had shorter mean durations from
diarrhea onset to specimen collection, and lower BUN val-
ues within 7 days of admission than did culture-negative E.
coli  O157 patients (Table 2). A higher proportion of
patients with outbreak-related HUS cases had positive E.
coli O157 cultures (13/15, 87%) than those with nonout-
break-related cases (21/50, 42%). 
Conclusions
Most surveillance systems for communicable disease
reporting are passive. The use of hospital discharge records
is a conventional method to verify the completeness of
reporting. Apopulation-based study that used hospital data
without reviewing medical charts estimated that 47% of
hospital discharge data were reported to public health sur-
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Table 1. Demographic and clinical characteristics of 65 patients 
with confirmed or probable hemolytic uremic syndrome (HUS), 
New York, 1998–1999 
Characteristic  No. of patients (N = 65) 
Demographic features   No. (incidence/100,000) 
Age (in years)       
<5  28 (2.0)     
5–14  11 (0.4)     
15–64  17 (0.1)     
>65  9 (0.3)     
Sex       
Male  20 (0.2)     
Female  45 (0.4)     
Race       
White  57 (0.3)     
Black  3 (0.2)     
Asian  1 (0.2)     
Outcome   No.( %)     
Alive  59 (91)     
Dead  6 (  9)     
Outbreak-associated  No. (%)     
Yes  15 (23)     
No  50 (77)     
Clinical features   No.( %)     
Diarrhea  62 (95)     
Protein in urine  52 (80)     
Blood in urine  52 (80)     
Any transfusion  50 (77)     
Blood in stool  46 (71)     
E. coli isolated  34 (52)     
Fever  30 (46)     
Vomiting  28 (43)     
Hemodialysis  19 (29)     
Treated with antimicrobial 
agents 
20 (31)     
Laboratory test results   Mean  Median  Range 
Creatinine (mg/dL)  4.1  3.3  0.3 – 13.2 
Blood urea nitrogen (mg/dL)  72.0  69.0  8.0 – 146.0 
Platelet/1,000  55.0  38.0  5.0 – 298.0 
Leukocytes/1,000  20.1  19.6  7.0 – 47.0 
Hematocrit (%)  21.9  21.3  9.4 – 35.5 
 veillance (14). Our disease surveillance system’s sensitiv-
ity of 65% in identifying diarrhea-associated HUS was
higher than that figure but also reinforces the importance
of medical chart audit. A possible contributing reason for
the low sensitivity may be the difficulty in identifying con-
firmed HUS cases. To enhance surveillance, New York, as
a FoodNet site, extended the chart review for hospitalized
patients <18 years of age statewide in whom HUS was
diagnosed. 
Seven of the 12 probable HUS case-patients had E. coli
O157:H7 isolated without evidence of erythrocyte frag-
mentation, suggesting that hospitals may not report proba-
ble cases. Astudy to match E. coli O157:H7 cases from our
surveillance system against HUS diagnosed cases from a
hospital discharge data system and to review all case-
patients hospitalized with E. coli O157:H7 is under way.
Results should identify the possible diarrhea-associated
HUS cases missed by our surveillance system. 
This study showed that female patients had higher inci-
dence rates for HUS; the incidence rates of E. coli
O157:H7 showed no differences by gender. E. coli
O157:H7 was isolated from stool or urine samples from 34
(63%) of 54 confirmed and probable HUS patients who
were cultured, a finding that demonstrates that E. coli
O157:H7 is the predominant organism related to diarrhea-
associated HUS in New York. Other studies have had sim-
ilar findings (15,16). Samples from HUS patients cultured
on or before the hospital admission date had a higher
recovery rate of E. coli O157 from stool cultures (78%)
than those cultured after hospital admission (41%).
Patients who did not have E. coli O157:H7 isolated were
cultured later in illness (6 days) than those from whom this
pathogen was recovered (4 days), a finding that reempha-
sizes the importance of obtaining early cultures for micro-
biologic diagnosis (17).
HUS associated with E. coli O157:H7 infection is a
serious illness with a 5%–10% death rate (5). Prompt fol-
lowup of cases using pulsed-field gel electrophoresis
molecular methods has increasingly led to identifying food
sources and removing contaminated products from the
food distribution system. Complete and rapid reporting of
cases is a crucial component of public health prevention
activities. 
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